NZMA Home

Table of contents
Current issue
Search journal
Archived issues
NZMJ Obituaries 1887-2008
Classifieds
Hotline (free ads)
How to subscribe
How to contribute
How to advertise
Contact Us
Copyright
Other journals
The New Zealand Medical Journal

 Journal of the New Zealand Medical Association, 23-March-2007, Vol 120 No 1251

Endoluminal repair of abdominal aortic aneurysm: the Middlemore Hospital experience
Janaka Wickremesekera, Wilbur Farmillo, Stewart Hawkins, Homayoun Zargar, Anwar Choudhary, Peter Vanniasingham
Abstract
Introduction With endoluminal stent graft (ESG) repair of abdominal aortic aneurysms (AAA) becoming more common, the morphological boundaries are constantly being pushed in deciding which patients to offer this mode of surgical management. In our tertiary hospital we have a relatively strict morphological selection as well as a multidisciplinary team that provides a good platform for performing endoluminal AAA repair.
Method A retrospective audit of patients undergoing elective endoluminal AAA repair at Middlemore Hospital (Otahuhu, Auckland, New Zealand) between 1999 and 2005 was performed; 40 patients were identified during this period and all records were reviewed. Prior to surgery, all patients had CT aortography with 3D-reconstruction, and each case was discussed at a multidisciplinary team meeting (vascular surgeons and interventional radiologists present). Patients less than 65 years of age were excluded from this endoluminal assessment. A strict morphological selection criteria was applied and adhered to.
Results Forty patients underwent elective endoluminal AAA repair between 1999 and 2005—5:1 male:female ratio and mean age 73.4 years. Fifty percent of patients had a history of ischaemic heart disease, 48% had known hypertension, 33% had known pulmonary disease, 12% had known diabetes mellitus, while a previous stroke, chronic renal failure, and current smokers respectively accounted for 18%. The American Society of Anaesthesiology (ASA) classification was used to assess patient fitness for surgery. Eighty percent of patients in this study had an ASA of III, 15% had an ASA of II, and the remaining patients had an ASA of IV. These figures are similar to Australian audit data (audit undertaken by ASERNIP-S). Morphology AAA showed mean diameter AAA of 5.2cm (4.3–6.7cm). Most AAA were fusiform (fusiform 90% vs saccular10%). All grafts were of Zenith Cook type bifurcated grafts. There were 2 endoleaks (5%)—type II endoleaks that were sealed with endovascular therapy; 2 patients returned to theatre for embolic complications with good postoperative result; and 1 patient died due to myocardial infarction (MI) postprocedure (mortality 2.5%).
Primary technical success was 95% and secondary technical success 100%. There were no conversions to open surgery and no procedural-related deaths.
Conclusion This audit from Middlemore Hospital shows good results can be achieved using strict morphological selection criteria and a multidisciplinary approach to treatment for ESG of AAA.

Endoluminal stent grafting (ESG) has extensively studied since Juan Parodi’s first report of abdominal aortic aneurysm (AAA) stenting in 1991.1 There has been much debate about whether endoluminal or open repair of AAA is superior technique in term of risks to the patient and longevity. Most vascular surgeons would agree that both procedures have an important place in the armamentarium to treat AAA. With the recent conclusion of randomised trials many of these issues would be shelved, however there seem to be more questions than answers when looking through the literature.2–5
Open repair has a proven track record and though has increased early morbidity and mortality in comparison to ESG, there is no difference in the mortality figures in the longer term.5,6 In addition, after open repair there is little need for long-term surveillance and the associated costs. In other words, once open repair is performed, the problem usually remains “fixed”. With ESG complication, the need for reintervention is required in up to 40% of patients4. It has, however, been shown that good case selection and planning reduces the risk for secondary intervention.
The approach at Middlemore Hospital has been of strict morphological selection criteria of AAA for ESG and a multidisciplinary approach to planning. The aim of this audit is to show that this policy produces good results in terms of morbidity and mortality.

Methods

Middlemore Hospital is a tertiary centre serving a population of approximately 450,000 people in the south Auckland region. Three surgeons perform ESG on their patients at Middlemore with respective teams which include interventional radiologists, nursing and theatre staff. All patients are discussed at the multidisciplinary planning meeting prior to undergoing treatment which involve all the above members.
Strict morphological criteria are adhered to including neck diameter <28 mm or less, neck length >20 mm, and angulation ≤60 degree angle. No circumferential mural thrombus should be present. Iliacs had to be >7 mm in diameter with minimal tortuosity. On CT there should be no significant horizontal portion , splaying, or S shape. There should be good landing zone with a vessel diameter not <22 mm and >20 mm length. Iliac, or common femoral artery (CFA) aneurysm were excluded. Anything more than minimal iliac calcification was also excluded.
All patients having had ESG of AAA at Middlemore Hospital were retrospectively identified from the hospital database. Forty patients were found to have had ESG and their medical records were reviewed.
Relevant data were collected, particular those emphasising consistency in preoperative assessment

Results

All 40 patients received elective AAA repairs; their procedures were performed between 1998–2005.
Most patients were male (5:1 male:female ratio); mean age 73.4 yrs (65–88 yrs). All patients were given Anaesthesiology Society of America (ASA) criteria by the attending anaesthetist. Most (80%) patients were classified as ASA III (Figure 1). Not surprisingly the most common patient comorbidities were ischaemic heart disease (IHD), hypertension (HT), and respiratory problems (Table 1; Figure 2).
Figure 1. Anaesthesiology Society of America (ASA) criteria
(MMH=Middlemore Hospital; ASERNIP–S=Australian Safety and Efficacy Registry for New Interventional Procedure–surgical)
Figure 2. Comorbidity distribution
(IHD=ischaemic heart disease; MI=myocardial infarction; HT=hypertension; Pulm(onary); CVA=cerebrovascular accident; DM=diabetes mellitus; CRF=chronic renal failure; Smok(ing)
Table 1. Patient characteristics
Comorbidity
Number of patients (total=40)
Ischaemic heart disease
Myocardial infarction
Hypertension
Pulmonary
CVA
Diabetes mellitus
Chronic renal failure
Smoker
Ex-smoker
Other
20
10
19
13
7
5
7
7
20
12
Morphology AAA—The majority of AAA were fusiform morphology (90%)with mean diameter of 5.2 cm(4.3–6.7). The grafts were bifurcated in the vast majority (39/40) and all were Zenith Cook grafts (Figure 3).
Figure 3. AAA stent (Zenith-Cook device)
Preoperative evaluation was extensive and included CT aortography with 3D reconstruction (Figure 4). Subsequently their case and investigations were discussed at the multidisciplinary planning meeting.
Figure 4. CT Aortography with 3-D reconstruction
All procedures were performed by multidisciplinary team (MDT) which always included a vascular surgeon and interventional radiologist. Most procedures were performed in theatre (33/40) and more recently with the opening of angiography-suite remaining cases were performed there. All patients had general anaesthetic (GA) for the procedure. All patients had surgical common femoral artery (CFA) access for their procedures (Figure 5). Procedure time was variable mean 149 minutes (57–222 min).
Hospital stay was a mean of 5.5 days (vs 7.4 days for ESG recorded in the Australian safety and efficacy registry for new interventional procedure-surgical (ASERNIP-S) database) with no patients requiring ICU admission.
Figure 5. Open common femoral artery access
All patients were followed up in clinic under strict CT and Ultrasound-based protocol (see Figure 6) with a mean follow-up 37.9 months (2–88 months).
Morbidity was categorised into local/graft related and systemic complications (Table 2). There were 2 patients with endoleak that required further intervention. Both were type II endoleaks that were sealed with angiographic coil embolisation. Both patients had successful treatment of backbleeding vessels.
Three patients had minor groin complications such as cellulitis and lymph leak that settled again with antibiotics and non-operative treatment;2 patients returned to theatre for distal embolic complication of lower limbs. Both had embolectomy which was successful. There was one death secondary to myocardial infarction giving mortality rate of 2.5%.
Primary technical success was 95%. Secondary technical success 100%. There were no conversions to open surgery and there were no procedural-related deaths.
Table 2. Post procedural morbidity of Middlemore Hospital’s AAA patients
Complications
Number of patients (total=40)
Systemic
Myocardial infarction/death
Urinary retention
Local/graft related
Endoleak (requiring re-intervention)
Groin complication
Embolic complication

1
2

2 (type II leaks requiring endovascular treatment)
3
3 (2 patients required embolectomy)
Figure 6. Surveillance protocol for AAA at Middlemore Hospital

Discussion

ESG of AAA repair has become part of the important part of the armamentarium of vascular surgeons and interventionalist throughout world. In larger tertiary institutions ESG is being performed more frequently and with that experience more challenging cases are selected.6 However the question is in centres that are selecting increasingly complex cases is there an associated increase in procedural related complications and poorer outcomes?
Middlemore Hospital’s AAA patient male:female ratio, age distribution, and patient comorbidities are similar to other centres.7–9 It is well known that the majority of AAA are fusiform, but in our study several patients had saccular aneurysms.
These aneurysms have a tendency to rupture at smaller diameters than fusiform aneurysms.10 Also these patient saccular aneurysms seem to have a higher predicted mortality if their aneurysms rupture so there is greater benefit to operate on them early.11 This along with female patient population caused our mean diameter of operated aneurysms to be at the lower end of those normally offered surgery. The recent UK Aneurysm Study showed patients with aneurysms measuring 5.5cm should be offered surgery.12 However other factors need to be taken into consideration such as sex of the patient, rate of expansion of the aneurysm, patient age and comorbidities, life expectancy, and the patient preferences.13
This audit of experience in a tertiary centre like Middlemore Hospital where vascular surgeons and their teams have chosen a more conservative approach shows that with good selection criteria and despite small numbers good results can be achieved. Low morbidity and primary and secondary technical success of 95% and 100% respectively, with no conversion to open surgery or procedural-related deaths (or more importantly no aneurysm-related deaths) shows good practice at Middlemore Hospital.
The endoleak rate in this series that required further intervention was 5%. Endoleak can be categorised into five types (see Table 3). The most clinically relevant are type I and III leaks that result in failure of exclusion of the aneurysm once the graft is in place.
Type I can occur if there is failure to properly seal the proximal or distal ends of the graft. Type III is due leakage between modules of the graft. Endoleak of this nature results in failure of exclusion of the aneurysm and the sac will continue to expand and risk of rupture persists if the endoleak is not corrected. These endoleaks should be recognised and corrected (ideally at the time of the procedure).
Interventionalists debate the significance of type II endoleaks, as many of these leaks will spontaneously resolve, regardless of graft type. Additionally, some patients will demonstrate stability or even shrinkage of the aneurysm sac in the presence of a patent type II endoleak. The rate of endoleak and the lack of more serious type I and III compares well with larger randomised series.4 In the EVAR I study there was 23% rate of endoleak, with 8% requiring reintervention.
We can conclude that the practice in Middlemore Hospital a tertiary centre with conservative selection and small numbers are good and compare well with larger centres.
Table 3. Classification of endoleak
Type I
Endoleak from non sealed top or bottom end of endograft
Type II
Endoleak from backbleeding sidebranch such as lumbar or inferior mesenteric artery?
Type III
Endoleak from between modules of endograft or hole in the graft
Type IV
Endoleak from the endograft wall secondary to graft porosity
Type V
Endotension – Endoleak not sourced but present as the sac maybe increasing. Thought to be secondary to mural thrombus at ends of graft or clot in side branches allowing transmission of systemic pressure to the sac
Competing interests: None.
Author information: Janaka Wickremesekera, Vascular Fellow, Capital Coast Health, Wellington; R Wilbur Farmillo, Vascular and General Surgeon, Middlemore Hospital; Stewart Hawkins, Interventional Radiologist, Middlemore Hospital; Homayoun Zargar, General Surgical Registrar, Hutt Hospital; Anwar Choudhary, Vascular Surgical House Surgeon, Capital Coast Health, Wellington; Peter Vanniasingham, Head of Vascular Surgery, Middlemore Hospital, Auckland
Correspondence: Janaka Wickremesekera, Capital and Coast District Health Board, PO Box 7343, Wellington. Fax: (04) 389 5318; email:Janaka.Wickremesekera@ccdhb.org.nz
References:
  1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Annals of Vascular Surgery. 1991;5:491–9.
  2. The UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998;352:1649–55.
  3. UK Small Aneurysm Trial Participants. Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet. 1998;352:1656–60.
  4. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet. 2005;365:2187–92.
  5. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet. 2005;365(9478):2179–86.
  6. Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. J Vasc Surg. 2006;43:446–51; discussion 51–2.
  7. Boult M, Babidge W, Anderson J, et al. Australian audit for the endoluminal repair of abdominal aortic aneurysm: the first 12 months. A N Z J Surg. 2002;72:190–5.
  8. Boult M, Babidge W, Maddern G, Fitridge R. Endoluminal repair of abdominal aortic aneurysm-contemporary Australian experience. Eur J Vasc Endovasc Surg. 2004;28:36–40.
  9. Harris PL, Buth J. An update on the important findings from the EUROSTAR EVAR registry. Vascular. 2004;12:33–8.
  10. Faggioli GL, Stella A, Gargiulo M, et al. Morphology of small aneurysms: definition and impact on risk of rupture. American Journal of Surgery 1994;168:131–5.
  11. Koskas F, Kieffer E. Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Annals of Vascular Surgery. 1997;11:90–9.
  12. Brady AR, Fowkes FG, Greenhalgh RM, et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm Trial participants. The British Journal of Surgery. 2000;87:742–9.
  13. Brewster DC, Cronenwett JL, Hallett JW, Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003;37:1106–17.
     
Current issue | Search journal | Archived issues | Classifieds | Hotline (free ads)
Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals